Frier Levitt Partner Lucas Morgan’s article, “Navigating State Boards of Pharmacy: Insights and Strategies for Pharmacies and Pharmacists,” was featured in Pharmacy Practice News on June 1, 2023. Lucas emphasizes the importance of pharmacists... Read More
Yesterday, the Supreme Court issued a joint opinion in the SuperValu and Safeway cases, unanimously holding that the scienter element of the False Claims Act (“FCA”) refers to a defendant’s knowledge and subjective beliefs rather than what an... Read More
In the rapidly evolving landscape of healthcare, small and medium-sized home healthcare providers play a crucial role in delivering quality care to individuals in need. As home healthcare continues to provide better access, improve outcomes and save... Read More
In a significant victory, Frier Levitt assisted a New York based pharmacy client in successfully challenging audit findings by a major Pharmacy Benefit Manager (“PBM”) resulting in the retrieval of over $1.1 million. In the Initial Findings,... Read More
Frier Levitt Life Sciences attorneys, Dae Y. Lee, Pharm.D., Esq., CPBS and Jonathan Levitt, Esq. co-authored an article titled: “The Consolidated Appropriations Act and PBM Transparency” in Pharmaceutical Commerce on May 12, 2023. In this... Read More
In recent years, the government has intensified its scrutiny of healthcare providers, with a particular focus on pharmacies. Independent pharmacies and pharmacy owners must be aware of a growing trend in government investigations regarding the... Read More
On December 22, 2022, the Pennsylvania Department of Human Services released a Medical Assistance (“MA”) Program Bulletin (“Bulletin”) applicable to 340B covered entities enrolled in the MA program. The Bulletin, which took effect on January... Read More
In a significant development that could impact the future of prescription drug costs, the U.S. Federal Trade Commission (“FTC”) announced an expansion of its investigation into the country’s leading Pharmacy Benefit Managers (“PBMs”). ... Read More
Pharmacies face serious PBM risks when issues that arise in audits are not properly addressed from recoupments and network terminations, to governmental investigations. Preparation and preventative measures are key to ensuring a positive audit... Read More
Frier Levitt Life Sciences attorneys, Dae Y. Lee, Pharm.D., Esq., CPBS and Jonathan Levitt, Esq. co-authored an article titled: “The Consolidated Appropriations Act and PBM Transparency” in Pharmaceutical Executive on May 12, 2023. In this... Read More
